International Bancshares, Hansen Natural, Genomic Health and Gold Fields

CHICAGO--([ BUSINESS WIRE ])--Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List a" Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): International Bancshares Corp. (Nasdaq: [ IBOC ])and Hansen Natural Corp. (Nasdaq: [ HANS ]). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Genomic Health, Inc. (Nasdaq: [ GHDX ]) and Gold Fields Ltd. (NYSE: [ GFI ]). To see the full Zacks #5 Rank List - Stocks to Sell Now visit: [ http://at.zacks.com/?id=92 ]

"Earnings estimate revisions are the most powerful force impacting stock prices."

Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List of Stocks to Sell Now by 80% annually (+2% vs. +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why IBOC and HANS have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:

International Bancshares Corp. (Nasdaq: [ IBOC ]) announced first-quarter earnings per share of 42 cents on May 5, missing the Zacks Consensus Estimate by 11%. The Zacks Consensus Estimate for the full year slipped 18 cents to a profit of $1.46 per share in the last month, which reflected downward revision by the only covering analyst. The following yeara�s forecast declined 8 cents to $1.60 per share during that time.

Hansen Natural Corp. (Nasdaq: [ HANS ]) posted first-quarter earnings of 35 cents per share on May 6, which came in nearly 24% behind analystsa� projections. Sales dipped 2.5% to $238.1 million. The Zacks Consensus Estimate for the current year decreased 18 cents to a profit of $2.30 per share over the past month as all of the 9 covering analysts reduced forecasts. Next yeara�s estimate fell 25 cents to $2.57 per share in that period.

Here is a synopsis of why GHDX and GFI have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks;

Genomic Health, Inc. (Nasdaq: [ GHDX ]) incurred a loss of 7 cents per share in its first quarter, reported last month, lagging analystsa� expectations for a loss of 3 cents. The Zacks Consensus Estimate for 2010 slid to a profit of 3 cents from 6 cents per share in the last 30 days as 5 analysts out of 13 lowered anticipations. The same time span has seen a drop of 3 cents in the forecast for 2011, which now stands at 35 cents per share.

Gold Fields Ltd.a�s (NYSE: [ GFI ]) third-quarter earnings of 6 cents per share, announced on May 7, missed analystsa� projections by 70%. In the prior-year period, the company earned 21 cents per share. For 2010, the Zacks Consensus Estimate fell 9 cents to 66 cents per share over the past month as 2 analysts out of 4 revised downward. The average forecast for next year moved down 5 cents to $1.03 per share in the same period.

Truly taking advantage of the Zacks Rank requires the understanding of how it works. The free special report; aZacks Rank Guide: Harnessing the Power of Earnings Estimate Revisionsa is available to provide this insightful background. Download a free copy now to prosper in the years to come at [ http://at.zacks.com/?id=93 ]

About the Zacks Rank

Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." Since inception in 1988, #1 Rank Stocks have generated an average annual return of +27%. During the 2000-2002 bear market, Zacks #1 Rank stocks gained +43.8%, while the S&P 500 tumbled -37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have significantly underperformed the S&P 500 (-0.9% versus +9%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.

Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.

Zacks aProfit from the Prosa e-mail newsletter offers continuous coverage of Zacks Rank Buy stocks and highlights those stocks poised to outperform the market. Subscribe to this free newsletter today by visiting [ http://at.zacks.com/?id=94 ]

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=95 ]

Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

N@N

International Bancshares, Hansen Natural, Genomic Health and Gold Fields